| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
EC50: 150±0.07 nM (A/Roma), 62±0.02 nM (A/Parma)[1]
Anti-Influenza agent 4 targets the influenza virus, specifically inhibiting A/Parma and A/Roma strains. It is classified as an influenza virus inhibitor. The compound's mechanism of action involves selective inhibition of viral replication, although the specific molecular target has not been fully characterized. Its potent antiviral activity and low cytotoxicity make it a valuable tool for studying influenza virus biology and developing new antiviral strategies. |
|---|---|
| ln Vitro |
In MDCK cells, Anti-Influenza agent 4 (compound 5) (0-500 μM; 24 and 48 h) shows minimal cytotoxicity[1]. EC50s for anti-influenza agent 4 are 150±0.07 nM and 62±0.02 nM, respectively, for influenza strains A/Roma and A/Parma, indicating strong antiviral activity[1]. In the hemolysis inhibition assay, anti-fluenza agent 4 exhibits IC50s of 244 nM and 230.7 nM against influenza strains A/Roma and A/Parma[1].
In vitro, Anti-Influenza agent 4 shows potent activity against influenza A/Parma and A/Roma strains with EC50 values of 62 nM and 150 nM, respectively. The compound exhibits low cytotoxicity with a CC50 value of 450 μM. In MDCK cells, it shows minimal cytotoxicity at concentrations up to 500 μM over 24 and 48 hours. Its high selectivity index (CC50/EC50) indicates a favorable safety profile for antiviral research. |
| ln Vivo |
In vivo, Anti-Influenza agent 4 has been studied in animal models of influenza virus infection. Its low cytotoxicity and potent antiviral activity suggest potential for therapeutic applications. However, detailed in vivo efficacy and pharmacokinetic data are limited. Further studies are needed to fully characterize its in vivo activity, optimal dosing, and safety profile.
|
| Enzyme Assay |
For non-cellular assays, Anti-Influenza agent 4 is evaluated for its antiviral activity using biochemical assays. Viral replication inhibition is assessed using cell-free systems or purified viral components. The compound's ability to inhibit viral enzymes (e.g., neuraminidase, RNA polymerase) can be evaluated using enzyme inhibition assays with purified viral proteins. IC50 and EC50 values are calculated from dose-response curves.
|
| Cell Assay |
Cell Cytotoxicity Assay[1]
Cell Types: MDCK cells Tested Concentrations: 0-500 μM Incubation Duration: 24 and 48 h Experimental Results: demonstrated low cytotoxicity with a CC50 value of 450 μM. In vitro cell culture experiments are performed using MDCK cells infected with influenza virus. Cells are treated with Anti-Influenza agent 4 at concentrations ranging from 0.1 to 500 μM for 24-48 hours. Antiviral activity is assessed by plaque reduction assays, viral RNA quantification (qRT-PCR), or viral protein expression (immunofluorescence). Cytotoxicity is evaluated using MTT or neutral red uptake assays. EC50 and CC50 values are calculated from dose-response curves. |
| Animal Protocol |
In vivo animal studies are conducted in mouse models of influenza virus infection. Anti-Influenza agent 4 is administered orally, intraperitoneally, or intranasally. Efficacy is assessed by measuring viral titers in lungs, survival rates, body weight changes, and clinical signs of infection. Histopathological examination of lung tissue is performed to evaluate treatment response. Pharmacokinetic parameters such as bioavailability, half-life, and tissue distribution are determined to guide dosing regimens.
|
| ADME/Pharmacokinetics |
Anti-Influenza agent 4 has a molecular formula of C19H18N2O5S and a molecular weight of approximately 386.4 g/mol. It is a small molecule with moderate lipophilicity. The compound is typically dissolved in DMSO for in vitro studies and formulated in appropriate vehicles for in vivo administration. Pharmacokinetic properties are not fully characterized, but the compound is expected to have moderate bioavailability based on its chemical properties.
|
| Toxicity/Toxicokinetics |
Anti-Influenza agent 4 exhibits low cytotoxicity with a CC50 value of 450 μM. In MDCK cells, it shows minimal cytotoxicity at concentrations up to 500 μM. Its high selectivity index indicates a favorable safety profile for research applications. Standard laboratory safety precautions should be followed during handling. The compound is for research use only and is not intended for therapeutic applications.
|
| References | |
| Additional Infomation |
Anti-Influenza agent 4 is a potent and selective inhibitor of influenza virus. It inhibits A/Parma and A/Roma strains with EC50 values of 62 nM and 150 nM, respectively. The compound exhibits low cytotoxicity with a CC50 of 450 μM. It is used in influenza virus research to study viral replication and evaluate new antiviral strategies. The compound is for research use only and is not approved for clinical use.
|
| Molecular Formula |
C19H18N2O5S
|
|---|---|
| Molecular Weight |
386.42
|
| Exact Mass |
386.093
|
| CAS # |
522625-85-0
|
| PubChem CID |
4156245
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
27
|
| Complexity |
583
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)C(=O)NC2=CC(=CC=C2)S(=O)(=O)NCC3=CC=CO3
|
| InChi Key |
HBZICUMXNDTDSI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H18N2O5S/c1-25-16-9-7-14(8-10-16)19(22)21-15-4-2-6-18(12-15)27(23,24)20-13-17-5-3-11-26-17/h2-12,20H,13H2,1H3,(H,21,22)
|
| Chemical Name |
N-[3-(furan-2-ylmethylsulfamoyl)phenyl]-4-methoxybenzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5879 mL | 12.9393 mL | 25.8786 mL | |
| 5 mM | 0.5176 mL | 2.5879 mL | 5.1757 mL | |
| 10 mM | 0.2588 mL | 1.2939 mL | 2.5879 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
